Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Use of genetic modifications in human gene chk1 which codes for checkpoint kinase 1

Inactive Publication Date: 2010-05-27
UNIV DUISBURG ESSEN
View PDF3 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0009]The invention is therefore based on the object to provide a means, which enables a better prognosis of the natural progression of a cancer and the response to any form of treatment. In particular, this means is to be able to detect those patients, in which increased DNA repair mechanisms aggravate a cancer treatment. The invention is further based on the object to provide a means to generally predict disease risks and progression of diseases, since DNA repair mechanisms are also very important for other diseases.

Problems solved by technology

In addition, some relatively unspecific serological markers exist.
This organizational principle though is functional, but on closer inspection it becomes clear that the cell cycle is far more complex.
As a consequence, the CDC protein is no longer able to activate the Cyclin complexes, due to which neither the S-phase can be advanced nor the M-phase started.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Use of genetic modifications in human gene chk1 which codes for checkpoint kinase 1
  • Use of genetic modifications in human gene chk1 which codes for checkpoint kinase 1
  • Use of genetic modifications in human gene chk1 which codes for checkpoint kinase 1

Examples

Experimental program
Comparison scheme
Effect test

example 1

Urinary Bladder Carcinoma

[0084]Bladder cancer is a malignant tumor of the mucous membrane of the urinary bladder and most frequently occurs between the age of 60 and 70. Men are affected by it three times as often as women. In men, bladder cancer is the third most frequent type of cancer after lung and prostate cancer. Bladder cancer can be caused by external influences. The risk factors include smoking, permanent strain on the organism by chemicals, like for example colorants or analgesic misuse. In many patients, the examinations show that it is a superficial tumor. This can be removed by surgery using a cystoscope. More than 70% of the patients treated because of a superficial bladder carcinoma show tumor rescrudescence in progression. In that, in more than half the patients, rescrudescence tumors with non-muscle-invasive disease occur. These can be curatively treated or controlled, respectively, by transurethral resection. It is therefore important to detect these lesions early ...

example 2

Colorectal Carcinoma

[0086]The colorectal carcinoma is the most frequent type of tumor in the gastrointestinal tract and one of the main causes for tumor-related death worldwide (12-15% of the total cancer mortality). In Germany, the incidence is about 51,000 new cases per year. The average 5-year survival rate after tumor resection is only approx. 50%. Eating habits, cancer-promoting metabolites, exogenous carcinogens and certain predisposing diseases are included in the risk factors for the formation of a colorectal carcinoma. The standard method for predicting the progression of the disease is the TNM or UICC stage system, respectively. Patients with UICC stages III or IV generally have a worse prognosis than patients with UICC stages I or II. An adjuvant chemotherapy is performed for metastasized colorectal carcinomas (UICC stages III and IV) and can enhance the local effect of radiation therapy. A majority of these patients develops recrudescences or metastases, which makes inte...

example 3

Chronic Lymphatic Leukemia

[0089]Chronic lymphatic leukemia (CLL) is a chronic form of leukemia. Characteristic for the disease is a high number of abnormal lymphocytes. A total of 30 percent of all leukemic diseases are chronic lymphatic leukemias. The median disease age is 65 years. A CLL can be benign for up to 20 years, i.e. the patients show no symptoms except for enlarged lymph nodes, tiredness and lack of appetite. The treatment only starts, if the number of lymphocytes highly increases, the portion of erythrocytes and thrombocytes decreases, or other complications occur. An early treatment has no influence on the progression of the disease. The most important therapeutic measure is chemotherapy. The further the disease has progressed, the higher are the disturbances of health by the modification of the organ system. Depending on the Binet stage of the disease, the doctor can estimate the prognosis. The stage of a CLL is, among others, characterized by how many lymphocytes are...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
Magnetic fieldaaaaaaaaaa
Electric chargeaaaaaaaaaa
Electric chargeaaaaaaaaaa
Login to View More

Abstract

The invention relates to an in vitro method for predicting disease risks, progression of diseases, drug risks, success of treatment and for finding drug targets by looking for one or more genetic modifications in the promoter region of the CHK1 (CHEK1) gene on human chromosome 11q23, the genetic modifications being a substitution thymine for guanine in position -1143 in the promoter of CHK1, of thymine for cytosine in position -1400, a substitution of cytosine for thymine in position -1453 or an insertion of one cytosine in position -1454 and the genetic modifications being detected individually or in any combinations by way of known methods.

Description

TECHNICAL FIELD OF THE INVENTION[0001]The invention relates to an in vitro method for predicting disease risks, progression of diseases, drug risks and for finding drug targets.TECHNOLOGICAL BACKGROUND OF THE INVENTION[0002]Cancer cells are characterized by loss of contact inhibition and uncontrolled cell growth. Such modifications are triggered spontaneously or by noxae, so-called cancero-genes, which damage the genetic make-up. Such noxae include many chemicals, tobacco smoke, but also UV light. Besides that, genetic factors play a prominent role in the formation of cancer. Characteristic for cancer cells, beside their uninhibited growth, is also the tendency to form metastases in other organs.[0003]It is of exceedingly high medical relevance to define prognosis factors for the progression of cancers, which provide information about the response to certain forms of treatment or are generally predictive for the occurrence of metastases, tumor progression and survival. So far, progn...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C12Q1/68
CPCC12Q1/6883C12Q1/6886C12Q2600/172C12Q2600/118C12Q2600/106C12Q2600/156C12Q2600/112
Inventor RIEMANN, KATHRINSIFFERT, WINFRIED
Owner UNIV DUISBURG ESSEN
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com